Evidence map›Paper›PMID 28710178›Full record

Trial reportJournal of the American Heart Association2017

Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease.

Tarec K Elajami, Abdulhamied Alfaddagh, Dharshan Lakshminarayan, Michael Soliman, Madhuri Chandnani, Francine K Welty

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American Heart Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01624727 (Slowing HEART diSease With Lifestyle and Omega-3 Fatty Acids), which is not on this map. Cited by 31 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 3 pooled it
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01624727 nacompletednot on this map

Slowing HEART diSease With Lifestyle and Omega-3 Fatty Acids (HEARTS)

TypeinterventionalSponsorBeth Israel Deaconess Medical CenterRan2009 to 2015Enrolled338ConditionsCoronary Heart Disease, Metabolic SyndromeArmsOmega 3 acid ethyl esters
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. The Impact of Omega Fatty Acids on DKD: A Multimodal Study Integrating Mendelian Randomization, Proteomic Mediation Analysis, and Meta-Analysis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Tarec K ElajamiDivision of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Abdulhamied AlfaddaghDivision of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Dharshan LakshminarayanDivision of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Michael SolimanDivision of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Madhuri ChandnaniDivision of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Francine K WeltyDivision of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA fwelty@bidmc.harvard.edu.
Harvard University · USBeth Israel Deaconess Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlbuminuria is a marker of inflammation and an independent predictor of cardiovascular morbidity and mortality. The current study evaluated whether eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) supplementation attenuates progression of albuminuria in subjects with coronary artery disease. METHODS AND

resultsTwo-hundred sixty-two subjects with stable coronary artery disease were randomized to either Lovaza (1.86 g of EPA and 1.5 g of DHA daily) or no Lovaza (control) for 1 year. Percent change in urine albumin-to-creatinine ratio (ACR) was compared. Mean (SD) age was 63.3 (7.6) years; 17% were women and 30% had type 2 diabetes mellitus. In nondiabetic subjects, no change in urine ACR occurred in either the Lovaza or control groups. In contrast, ACR increased 72.3% (

conclusionsEPA and DHA supplementation attenuated progression of albuminuria in subjects with type 2 diabetes mellitus and coronary artery disease, most of whom were on an angiotensin-converting enzyme-inhibitor or angiotensin-receptor blocker. Thus, EPA and DHA supplementation should be considered as additional therapy to an angiotensin-converting enzyme-inhibitor or angiotensin-receptor blocker in subjects with type 2 diabetes mellitus and coronary artery disease. CLINICAL

trial registrationURL: http://www.clinicaltrials.gov. Unique identifier: NCT01624727.

Indexed as

Dietary SupplementsAdultAgedAged, 80 and overAlbuminuriaAngiotensin-Converting Enzyme InhibitorsAngiotensin II Type 1 Receptor BlockersBostonCoronary Artery DiseaseDiabetes Mellitus, Type 2Diabetic NephropathiesDisease ProgressionDocosahexaenoic AcidsDrug CombinationsEicosapentaenoic AcidFemaleAngiotensin-Converting Enzyme InhibitorsAngiotensin II Type 1 Receptor BlockersDocosahexaenoic AcidsDrug CombinationsEicosapentaenoic AcidOmacoralbuminuriaangiotensin‐converting enzyme inhibitorcoronary artery diseaseomega‐3 fatty acidstype 2 diabetes mellitus

Identifiers

PMID28710178
PMCPMC5586259
OpenAlexW2735345004

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.